{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:46:44Z","timestamp":1793969204207,"version":"4.8.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Discoveric bio alpha ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alpha-synuclein (aSyn) pathology is present in approximately 50% of Alzheimer\u2019s disease (AD) cases at autopsy and might impact the age-of-onset and disease progression in AD. Here, we aimed to determine whether tau and aSyn profiles differ between AD cases with Lewy bodies (AD-LB), pure AD and Parkinson\u2019s disease with dementia (PDD) cases using epitope-, post-translational modification- (PTM) and isoform-specific tau and aSyn antibody panels spanning from the N- to C-terminus. We included the middle temporal gyrus (MTG) and amygdala (AMY) of clinically diagnosed and pathologically confirmed cases and performed dot blotting, western blotting and immunohistochemistry combined with quantitative and morphological analyses. All investigated phospho-tau (pTau) species, except pT181, were upregulated in AD-LB and AD cases compared to PDD and control cases, but no significant differences were observed between AD-LB and AD subjects. In addition, tau antibodies targeting the proline-rich regions and C-terminus showed preferential binding to AD-LB and AD brain homogenates. Antibodies targeting C-terminal aSyn epitopes and pS129 aSyn showed stronger binding to AD-LB and PDD cases compared to AD and control cases. Two pTau species (pS198 and pS396) were specifically detected in the soluble protein fractions of AD-LB and AD subjects, indicative of early involvement of these PTMs in the multimerization process of tau. Other phospho-variants for both tau (pT212\/S214, pT231 and pS422) and aSyn (pS129) were only detected in the insoluble protein fraction of AD-LB\/AD and AD-LB\/PDD cases, respectively. aSyn load was higher in the AMY of AD-LB cases compared to PDD cases, suggesting aggravated aSyn pathology under the presence of AD pathology, while tau load was similar between AD-LB and AD cases. Co-localization of pTau and aSyn could be observed within astrocytes of AD-LB cases within the MTG. These findings highlight a unique pathological signature for AD-LB cases compared to pure AD and PDD cases.<\/jats:p>","DOI":"10.1007\/s00401-023-02657-y","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T02:02:26Z","timestamp":1704852146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Distinct tau and alpha-synuclein molecular signatures in Alzheimer\u2019s disease with and without Lewy bodies and Parkinson\u2019s disease with dementia"],"prefix":"10.1007","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9880-6525","authenticated-orcid":false,"given":"Bram L.","family":"van der Gaag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasja A. C.","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. P.","family":"Breve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G. J. M.","family":"Bol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allert J.","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. M.","family":"Hoozemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Courade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6175-5357","authenticated-orcid":false,"given":"Wilma D. J.","family":"van de Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"2657_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1750-3639.2008.00147.x","volume":"18","author":"I Alafuzoff","year":"2008","unstructured":"Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H et al (2008) Staging of neurofibrillary pathology in Alzheimer\u2019s disease: a study of the BrainNet Europe Consortium. Brain Pathol 18:484\u2013496. https:\/\/doi.org\/10.1111\/j.1750-3639.2008.00147.x","journal-title":"Brain Pathol"},{"key":"2657_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00401-009-0523-2","volume":"117","author":"I Alafuzoff","year":"2009","unstructured":"Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I et al (2009) Staging\/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 117:635\u2013652. https:\/\/doi.org\/10.1007\/s00401-009-0523-2","journal-title":"Acta Neuropathol"},{"key":"2657_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40478-017-0452-6","volume":"5","author":"S Arawaka","year":"2017","unstructured":"Arawaka S, Sato H, Sasaki A, Koyama S, Kato T (2017) Mechanisms underlying extensive Ser129-phosphorylation in alpha-synuclein aggregates. Acta Neuropathol Commun 5:48. https:\/\/doi.org\/10.1186\/s40478-017-0452-6","journal-title":"Acta Neuropathol Commun"},{"key":"2657_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/alz.12192","volume":"17","author":"AFT Arnsten","year":"2021","unstructured":"Arnsten AFT, Datta D, Del Tredici K, Braak H (2021) Hypothesis: tau pathology is an initiating factor in sporadic Alzheimer\u2019s disease. Alzheimers Dement 17:115\u2013124. https:\/\/doi.org\/10.1002\/alz.12192","journal-title":"Alzheimers Dement"},{"key":"2657_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s004010100423","volume":"103","author":"JC Augustinack","year":"2002","unstructured":"Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer\u2019s disease. Acta Neuropathol 103:26\u201335. https:\/\/doi.org\/10.1007\/s004010100423","journal-title":"Acta Neuropathol"},{"key":"2657_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41598-022-04780-4","volume":"12","author":"S Awa","year":"2022","unstructured":"Awa S, Suzuki G, Masuda-Suzukake M, Nonaka T, Saito M, Hasegawa M (2022) Phosphorylation of endogenous alpha-synuclein induced by extracellular seeds initiates at the pre-synaptic region and spreads to the cell body. Sci Rep 12:1163. https:\/\/doi.org\/10.1038\/s41598-022-04780-4","journal-title":"Sci Rep"},{"key":"2657_CR7","doi-asserted-by":"publisher","first-page":"e26609","DOI":"10.1371\/journal.pone.0026609","volume":"6","author":"N Badiola","year":"2011","unstructured":"Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Goncalves SA, Pera M et al (2011) Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS ONE 6:e26609. https:\/\/doi.org\/10.1371\/journal.pone.0026609","journal-title":"PLoS ONE"},{"key":"2657_CR8","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5","journal-title":"Sci Rep"},{"key":"2657_CR9","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.bpj.2010.06.035","volume":"99","author":"T Bartels","year":"2010","unstructured":"Bartels T, Ahlstrom LS, Leftin A, Kamp F, Haass C, Brown MF et al (2010) The N-terminus of the intrinsically disordered protein alpha-synuclein triggers membrane binding and helix folding. Biophys J 99:2116\u20132124. https:\/\/doi.org\/10.1016\/j.bpj.2010.06.035","journal-title":"Biophys J"},{"key":"2657_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bbadis.2004.08.014","volume":"1739","author":"LI Binder","year":"2005","unstructured":"Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW (2005) Tau, tangles, and Alzheimer\u2019s disease. Biochim Biophys Acta 1739:216\u2013223. https:\/\/doi.org\/10.1016\/j.bbadis.2004.08.014","journal-title":"Biochim Biophys Acta"},{"key":"2657_CR11","doi-asserted-by":"crossref","unstructured":"Br\u00e1s IC, Khani MH, Vasili E, M\u00f6bius W, Riedel D, Parfentev I, Gerhardt E, Fahlbusch C, Urlaub H, Zweckstetter M (2021) Common molecular mechanisms underlie the transfer of alpha-synuclein, Tau and huntingtin and modulate spontaneous activity in neuronal cells. bioRxiv","DOI":"10.1101\/2021.07.18.452825"},{"issue":"2","key":"2657_CR12","doi-asserted-by":"publisher","first-page":"100054","DOI":"10.1016\/j.xpro.2020.100054","volume":"1","author":"AC Chlebowski","year":"2020","unstructured":"Chlebowski AC, Kisby GE (2020) Protocol for high-throughput screening of neural cell or brain tissue protein using a dot-blot technique with near-infrared imaging. STAR Protoc 1(2):100054. https:\/\/doi.org\/10.1016\/j.xpro.2020.100054","journal-title":"STAR Protoc"},{"key":"2657_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00401-019-02087-9","volume":"139","author":"M Colin","year":"2020","unstructured":"Colin M, Dujardin S, Schraen-Maschke S, Meno-Tetang G, Duyckaerts C, Courade JP et al (2020) From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol 139:3\u201325. https:\/\/doi.org\/10.1007\/s00401-019-02087-9","journal-title":"Acta Neuropathol"},{"key":"2657_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ana.25392","volume":"85","author":"D Coughlin","year":"2019","unstructured":"Coughlin D, Xie SX, Liang M, Williams A, Peterson C, Weintraub D et al (2019) Cognitive and pathological influences of tau pathology in Lewy body disorders. Ann Neurol 85:259\u2013271. https:\/\/doi.org\/10.1002\/ana.25392","journal-title":"Ann Neurol"},{"key":"2657_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fneur.2013.00114","volume":"4","author":"CM Cowan","year":"2013","unstructured":"Cowan CM, Mudher A (2013) Are tau aggregates toxic or protective in tauopathies? Front Neurol 4:114. https:\/\/doi.org\/10.3389\/fneur.2013.00114","journal-title":"Front Neurol"},{"key":"2657_CR16","doi-asserted-by":"publisher","first-page":"e12295","DOI":"10.1002\/trc2.12295","volume":"8","author":"J Cummings","year":"2022","unstructured":"Cummings J, Lee G, Nahed P, Kambar M, Zhong K, Fonseca J et al (2022) Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimers Dement (N Y) 8:e12295. https:\/\/doi.org\/10.1002\/trc2.12295","journal-title":"Alzheimers Dement (N Y)"},{"key":"2657_CR17","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1021\/acs.biochem.9b00215","volume":"58","author":"AKR Dasari","year":"2019","unstructured":"Dasari AKR, Kayed R, Wi S, Lim KH (2019) Tau interacts with the C-terminal region of alpha-synuclein, promoting formation of toxic aggregates with distinct molecular conformations. Biochemistry 58:2814\u20132821. https:\/\/doi.org\/10.1021\/acs.biochem.9b00215","journal-title":"Biochemistry"},{"key":"2657_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00401-022-02406-7","volume":"143","author":"L de Boni","year":"2022","unstructured":"de Boni L, Watson AH, Zaccagnini L, Wallis A, Zhelcheska K, Kim N et al (2022) Brain region-specific susceptibility of Lewy body pathology in synucleinopathies is governed by alpha-synuclein conformations. Acta Neuropathol 143:453\u2013469. https:\/\/doi.org\/10.1007\/s00401-022-02406-7","journal-title":"Acta Neuropathol"},{"key":"2657_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s40478-019-0823-2","volume":"7","author":"E Ercan-Herbst","year":"2019","unstructured":"Ercan-Herbst E, Ehrig J, Schondorf DC, Behrendt A, Klaus B, Gomez Ramos B et al (2019) A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer\u2019s disease brain. Acta Neuropathol Commun 7:192. https:\/\/doi.org\/10.1186\/s40478-019-0823-2","journal-title":"Acta Neuropathol Commun"},{"key":"2657_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","volume":"12","author":"CR Fields","year":"2019","unstructured":"Fields CR, Bengoa-Vergniory N, Wade-Martins R (2019) Targeting alpha-synuclein as a therapy for Parkinson\u2019s disease. Front Mol Neurosci 12:299. https:\/\/doi.org\/10.3389\/fnmol.2019.00299","journal-title":"Front Mol Neurosci"},{"key":"2657_CR21","doi-asserted-by":"publisher","first-page":"645233","DOI":"10.3389\/fncel.2021.645233","volume":"15","author":"RM Fleeman","year":"2021","unstructured":"Fleeman RM, Proctor EA (2021) Astrocytic propagation of tau in the context of Alzheimer\u2019s disease. Front Cell Neurosci 15:645233. https:\/\/doi.org\/10.3389\/fncel.2021.645233","journal-title":"Front Cell Neurosci"},{"key":"2657_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0","volume":"59","author":"BI Giasson","year":"2000","unstructured":"Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ et al (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson\u2019s disease. J Neurosci Res 59:528\u2013533. https:\/\/doi.org\/10.1002\/(SICI)1097-4547(20000215)59:4%3c528::AID-JNR8%3e3.0.CO;2-0","journal-title":"J Neurosci Res"},{"key":"2657_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/brain\/aww230","volume":"140","author":"M Goedert","year":"2017","unstructured":"Goedert M, Masuda-Suzukake M, Falcon B (2017) Like prions: the propagation of aggregated tau and alpha-synuclein in neurodegeneration. Brain 140:266\u2013278. https:\/\/doi.org\/10.1093\/brain\/aww230","journal-title":"Brain"},{"key":"2657_CR24","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.neurobiolaging.2004.09.019","volume":"26","author":"AL Guillozet-Bongaarts","year":"2005","unstructured":"Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T et al (2005) Tau truncation during neurofibrillary tangle evolution in Alzheimer\u2019s disease. Neurobiol Aging 26:1015\u20131022. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2004.09.019","journal-title":"Neurobiol Aging"},{"key":"2657_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mds.23455","volume":"26","author":"GM Halliday","year":"2011","unstructured":"Halliday GM, Stevens CH (2011) Glia: initiators and progressors of pathology in Parkinson\u2019s disease. Mov Disord 26:6\u201317. https:\/\/doi.org\/10.1002\/mds.23455","journal-title":"Mov Disord"},{"key":"2657_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement 8:1\u201313. https:\/\/doi.org\/10.1016\/j.jalz.2011.10.007","journal-title":"Alzheimers Dement"},{"key":"2657_CR27","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-021-01465-9","volume":"27","author":"E Jabbari","year":"2021","unstructured":"Jabbari E, Duff KE (2021) Tau-targeting antibody therapies: too late, wrong epitope or wrong target? Nat Med 27:1341\u20131342. https:\/\/doi.org\/10.1038\/s41591-021-01465-9","journal-title":"Nat Med"},{"key":"2657_CR28","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S1474-4422(22)00298-8","volume":"21","author":"CR Jack Jr","year":"2022","unstructured":"Jack CR Jr (2022) Advances in Alzheimer\u2019s disease research over the past two decades. Lancet Neurol 21:866\u2013869. https:\/\/doi.org\/10.1016\/S1474-4422(22)00298-8","journal-title":"Lancet Neurol"},{"key":"2657_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"2657_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","volume":"7","author":"S Jadhav","year":"2019","unstructured":"Jadhav S, Avila J, Scholl M, Kovacs GG, Kovari E, Skrabana R et al (2019) A walk through tau therapeutic strategies. Acta Neuropathol Commun 7:22. https:\/\/doi.org\/10.1186\/s40478-019-0664-z","journal-title":"Acta Neuropathol Commun"},{"key":"2657_CR31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/s0014-5793(96)01386-5","volume":"399","author":"T Kampers","year":"1996","unstructured":"Kampers T, Friedhoff P, Biernat J, Mandelkow EM, Mandelkow E (1996) RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett 399:344\u2013349. https:\/\/doi.org\/10.1016\/s0014-5793(96)01386-5","journal-title":"FEBS Lett"},{"key":"2657_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jprot.2012.11.019","volume":"79","author":"A Kan","year":"2013","unstructured":"Kan A, Mohamedali A, Tan SH, Cheruku HR, Slapetova I, Lee LY et al (2013) An improved method for the detection and enrichment of low-abundant membrane and lipid raft-residing proteins. J Proteomics 79:299\u2013304. https:\/\/doi.org\/10.1016\/j.jprot.2012.11.019","journal-title":"J Proteomics"},{"key":"2657_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3389\/fnagi.2020.00096","volume":"12","author":"GG Kovacs","year":"2020","unstructured":"Kovacs GG (2020) Astroglia and tau: new perspectives. Front Aging Neurosci 12:96. https:\/\/doi.org\/10.3389\/fnagi.2020.00096","journal-title":"Front Aging Neurosci"},{"key":"2657_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00401-015-1509-x","volume":"131","author":"GG Kovacs","year":"2016","unstructured":"Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H et al (2016) Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol 131:87\u2013102. https:\/\/doi.org\/10.1007\/s00401-015-1509-x","journal-title":"Acta Neuropathol"},{"key":"2657_CR35","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1212\/01.WNL.0000165987.89198.65","volume":"64","author":"ML Kraybill","year":"2005","unstructured":"Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD et al (2005) Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64:2069\u20132073. https:\/\/doi.org\/10.1212\/01.WNL.0000165987.89198.65","journal-title":"Neurology"},{"key":"2657_CR36","doi-asserted-by":"publisher","first-page":"105086","DOI":"10.1016\/j.nbd.2020.105086","volume":"146","author":"ST Kumar","year":"2020","unstructured":"Kumar ST, Jagannath S, Francois C, Vanderstichele H, Stoops E, Lashuel HA (2020) How specific are the conformation-specific \u03b1-synuclein antibodies? Characterization and validation of 16 \u03b1-synuclein conformation-specific antibodies using well-characterized preparations of \u03b1-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol Dis 146:105086","journal-title":"Neurobiol Dis"},{"key":"2657_CR37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH et al (2022) Trial of cinpanemab in early Parkinson\u2019s disease. N Engl J Med 387:408\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa2203395","journal-title":"N Engl J Med"},{"key":"2657_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-021-01127-4","volume":"9","author":"L Li","year":"2021","unstructured":"Li L, Shi R, Gu J, Tung YC, Zhou Y, Zhou D et al (2021) Alzheimer\u2019s disease brain contains tau fractions with differential prion-like activities. Acta Neuropathol Commun 9:1\u201318","journal-title":"Acta Neuropathol Commun"},{"key":"2657_CR39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3233\/jad-2007-12410","volume":"12","author":"J Luna-Munoz","year":"2007","unstructured":"Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R (2007) Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer\u2019s disease. J Alzheimers Dis 12:365\u2013375. https:\/\/doi.org\/10.3233\/jad-2007-12410","journal-title":"J Alzheimers Dis"},{"key":"2657_CR40","doi-asserted-by":"publisher","first-page":"e0217566","DOI":"10.1371\/journal.pone.0217566","volume":"14","author":"M Malek-Ahmadi","year":"2019","unstructured":"Malek-Ahmadi M, Beach TG, Zamrini E, Adler CH, Sabbagh MN, Shill HA et al (2019) Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS ONE 14:e0217566. https:\/\/doi.org\/10.1371\/journal.pone.0217566","journal-title":"PLoS ONE"},{"key":"2657_CR41","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1093\/brain\/awab011","volume":"144","author":"A Mate de Gerando","year":"2021","unstructured":"Mate de Gerando A, d\u2019Orange M, Augustin E, Josephine C, Auregan G, Gaudin-Guerif M et al (2021) Neuronal tau species transfer to astrocytes and induce their loss according to tau aggregation state. Brain 144:1167\u20131182. https:\/\/doi.org\/10.1093\/brain\/awab011","journal-title":"Brain"},{"key":"2657_CR42","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3233\/JAD-190256","volume":"69","author":"S Matsunaga","year":"2019","unstructured":"Matsunaga S, Fujishiro H, Takechi H (2019) Efficacy and safety of glycogen synthase kinase 3 inhibitors for Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimers Dis 69:1031\u20131039. https:\/\/doi.org\/10.3233\/JAD-190256","journal-title":"J Alzheimers Dis"},{"key":"2657_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrd2111","volume":"6","author":"MP Mazanetz","year":"2007","unstructured":"Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6:464\u2013479. https:\/\/doi.org\/10.1038\/nrd2111","journal-title":"Nat Rev Drug Discov"},{"key":"2657_CR44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3233\/JPD-229002","volume":"12","author":"K McFarthing","year":"2022","unstructured":"McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK et al (2022) Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2022 update. J Parkinsons Dis 12:1073\u20131082. https:\/\/doi.org\/10.3233\/JPD-229002","journal-title":"J Parkinsons Dis"},{"key":"2657_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement"},{"key":"2657_CR46","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/wnl.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al (1991) The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology 41:479\u2013486. https:\/\/doi.org\/10.1212\/wnl.41.4.479","journal-title":"Neurology"},{"issue":"3","key":"2657_CR47","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00401-021-02329-9","volume":"142","author":"TE Moors","year":"2021","unstructured":"Moors TE, Maat CA, Niedieker D, Mona D, Petersen D, Timmermans-Huisman E et al (2021) The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson\u2019s disease brain as revealed by multicolor STED microscopy. Acta Neuropathol 142(3):423\u2013448","journal-title":"Acta Neuropathol"},{"key":"2657_CR48","doi-asserted-by":"publisher","first-page":"167713","DOI":"10.1016\/j.jmb.2022.167713","volume":"435","author":"S Mukherjee","year":"2023","unstructured":"Mukherjee S, Sakunthala A, Gadhe L, Poudyal M, Sawner AS, Kadu P et al (2023) Liquid-liquid phase separation of alpha-synuclein: a new mechanistic insight for alpha-synuclein aggregation associated with Parkinson\u2019s disease pathogenesis. J Mol Biol 435:167713. https:\/\/doi.org\/10.1016\/j.jmb.2022.167713","journal-title":"J Mol Biol"},{"key":"2657_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40478-018-0557-6","volume":"6","author":"J Neddens","year":"2018","unstructured":"Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T et al (2018) Phosphorylation of different tau sites during progression of Alzheimer\u2019s disease. Acta Neuropathol Commun 6:52. https:\/\/doi.org\/10.1186\/s40478-018-0557-6","journal-title":"Acta Neuropathol Commun"},{"key":"2657_CR50","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362\u2013381. https:\/\/doi.org\/10.1097\/NEN.0b013e31825018f7","journal-title":"J Neuropathol Exp Neurol"},{"key":"2657_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JPD-160779","volume":"6","author":"A Oueslati","year":"2016","unstructured":"Oueslati A (2016) Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade? J Parkinsons Dis 6:39\u201351. https:\/\/doi.org\/10.3233\/JPD-160779","journal-title":"J Parkinsons Dis"},{"key":"2657_CR52","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1093\/brain\/awac171","volume":"145","author":"L Pan","year":"2022","unstructured":"Pan L, Li C, Meng L, Tian Y, He M, Yuan X et al (2022) Tau accelerates alpha-synuclein aggregation and spreading in Parkinson\u2019s disease. Brain 145:3454\u20133471. https:\/\/doi.org\/10.1093\/brain\/awac171","journal-title":"Brain"},{"key":"2657_CR53","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1001\/archneur.61.12.1915","volume":"61","author":"A Popescu","year":"2004","unstructured":"Popescu A, Lippa CF, Lee VM, Trojanowski JQ (2004) Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 61:1915\u20131919. https:\/\/doi.org\/10.1001\/archneur.61.12.1915","journal-title":"Arch Neurol"},{"key":"2657_CR54","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30:1591\u20131601","journal-title":"Mov Disord"},{"key":"2657_CR55","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41557-020-0465-9","volume":"12","author":"S Ray","year":"2020","unstructured":"Ray S, Singh N, Kumar R, Patel K, Pandey S, Datta D et al (2020) alpha-Synuclein aggregation nucleates through liquid-liquid phase separation. Nat Chem 12:705\u2013716. https:\/\/doi.org\/10.1038\/s41557-020-0465-9","journal-title":"Nat Chem"},{"key":"2657_CR56","doi-asserted-by":"publisher","first-page":"11835","DOI":"10.1523\/JNEUROSCI.0983-17.2017","volume":"37","author":"J Rostami","year":"2017","unstructured":"Rostami J, Holmqvist S, Lindstrom V, Sigvardson J, Westermark GT, Ingelsson M et al (2017) Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes. J Neurosci 37:11835\u201311853. https:\/\/doi.org\/10.1523\/JNEUROSCI.0983-17.2017","journal-title":"J Neurosci"},{"key":"2657_CR57","doi-asserted-by":"publisher","first-page":"14211","DOI":"10.1038\/srep14211","volume":"5","author":"A Sasaki","year":"2015","unstructured":"Sasaki A, Arawaka S, Sato H, Kato T (2015) Sensitive western blotting for detection of endogenous Ser129-phosphorylated alpha-synuclein in intracellular and extracellular spaces. Sci Rep 5:14211. https:\/\/doi.org\/10.1038\/srep14211","journal-title":"Sci Rep"},{"key":"2657_CR58","doi-asserted-by":"publisher","first-page":"102270","DOI":"10.1016\/j.pneurobio.2022.102270","volume":"214","author":"U Sengupta","year":"2022","unstructured":"Sengupta U, Kayed R (2022) Amyloid beta, Tau, and alpha-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol 214:102270. https:\/\/doi.org\/10.1016\/j.pneurobio.2022.102270","journal-title":"Prog Neurobiol"},{"key":"2657_CR59","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2019","unstructured":"Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP et al (2019) Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat Neurosci 22:1099\u20131109. https:\/\/doi.org\/10.1038\/s41593-019-0423-2","journal-title":"Nat Neurosci"},{"key":"2657_CR60","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/pro.4025","volume":"30","author":"A Siegert","year":"2021","unstructured":"Siegert A, Rankovic M, Favretto F, Ukmar-Godec T, Strohaker T, Becker S et al (2021) Interplay between tau and alpha-synuclein liquid-liquid phase separation. Protein Sci 30:1326\u20131336. https:\/\/doi.org\/10.1002\/pro.4025","journal-title":"Protein Sci"},{"key":"2657_CR61","doi-asserted-by":"publisher","first-page":"10224","DOI":"10.1074\/jbc.REV120.011743","volume":"295","author":"ZA Sorrentino","year":"2020","unstructured":"Sorrentino ZA, Giasson BI (2020) The emerging role of \u03b1-synuclein truncation in aggregation and disease. J Biol Chem 295:10224\u201310244","journal-title":"J Biol Chem"},{"key":"2657_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-019-01977-2","volume":"138","author":"ZA Sorrentino","year":"2019","unstructured":"Sorrentino ZA, Giasson BI, Chakrabarty P (2019) alpha-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Acta Neuropathol 138:1\u201321. https:\/\/doi.org\/10.1007\/s00401-019-01977-2","journal-title":"Acta Neuropathol"},{"key":"2657_CR63","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40478-019-0787-2","volume":"7","author":"ZA Sorrentino","year":"2019","unstructured":"Sorrentino ZA, Goodwin MS, Riffe CJ, Dhillon JS, Xia Y, Gorion KM et al (2019) Unique alpha-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression. Acta Neuropathol Commun 7:142. https:\/\/doi.org\/10.1186\/s40478-019-0787-2","journal-title":"Acta Neuropathol Commun"},{"key":"2657_CR64","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/brain\/awab099","volume":"144","author":"S Spina","year":"2021","unstructured":"Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C et al (2021) Comorbid neuropathological diagnoses in early versus late-onset Alzheimer\u2019s disease. Brain 144:2186\u20132198. https:\/\/doi.org\/10.1093\/brain\/awab099","journal-title":"Brain"},{"key":"2657_CR65","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00401-008-0366-2","volume":"115","author":"DR Thal","year":"2008","unstructured":"Thal DR, Griffin WS, de Vos RA, Ghebremedhin E (2008) Cerebral amyloid angiopathy and its relationship to Alzheimer\u2019s disease. Acta Neuropathol 115:599\u2013609. https:\/\/doi.org\/10.1007\/s00401-008-0366-2","journal-title":"Acta Neuropathol"},{"key":"2657_CR66","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/wnl.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791\u20131800. https:\/\/doi.org\/10.1212\/wnl.58.12.1791","journal-title":"Neurology"},{"key":"2657_CR67","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","volume":"14","author":"D Twohig","year":"2019","unstructured":"Twohig D, Nielsen HM (2019) alpha-Synuclein in the pathophysiology of Alzheimer\u2019s disease. Mol Neurodegener 14:23. https:\/\/doi.org\/10.1186\/s13024-019-0320-x","journal-title":"Mol Neurodegener"},{"key":"2657_CR68","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00401-015-1406-3","volume":"129","author":"L Walker","year":"2015","unstructured":"Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C et al (2015) Neuropathologically mixed Alzheimer\u2019s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol 129:729\u2013748. https:\/\/doi.org\/10.1007\/s00401-015-1406-3","journal-title":"Acta Neuropathol"},{"issue":"7","key":"2657_CR69","doi-asserted-by":"publisher","first-page":"e98049","DOI":"10.15252\/embj.201798049","volume":"37","author":"S Wegmann","year":"2018","unstructured":"Wegmann S, Eftekharzadeh B, Tepper K, Zoltowska KM, Bennett RE, Dujardin S et al (2018) Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J 37(7):e98049. https:\/\/doi.org\/10.15252\/embj.201798049","journal-title":"EMBO J"},{"issue":"1699\u20131713","key":"2657_CR70","first-page":"e1613","volume":"183","author":"H Wesseling","year":"2020","unstructured":"Wesseling H, Mair W, Kumar M, Schlaffner CN, Tang S, Beerepoot P et al (2020) Tau PTM profiles identify patient heterogeneity and stages of Alzheimer\u2019s disease. Cell 183(1699\u20131713):e1613","journal-title":"Cell"},{"key":"2657_CR71","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","volume":"26","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Bendlin BB (2021) Biomarkers for Alzheimer\u2019s disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry 26:296\u2013308. https:\/\/doi.org\/10.1038\/s41380-020-0721-9","journal-title":"Mol Psychiatry"},{"key":"2657_CR72","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3389\/fnins.2019.00381","volume":"13","author":"J Zhang","year":"2019","unstructured":"Zhang J, Li X, Li JD (2019) The roles of post-translational modifications on alpha-synuclein in the pathogenesis of Parkinson\u2019s diseases. Front Neurosci 13:381. https:\/\/doi.org\/10.3389\/fnins.2019.00381","journal-title":"Front Neurosci"},{"issue":"2","key":"2657_CR73","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41593-022-01239-7","volume":"26","author":"S Zhang","year":"2023","unstructured":"Zhang S, Zhu R, Pan B, Xu H, Olufemi MF, Gathagan RJ et al (2023) Post-translational modifications of soluble alpha-synuclein regulate the amplification of pathological alpha-synuclein. Nat Neurosci 26(2):213\u2013225. https:\/\/doi.org\/10.1038\/s41593-022-01239-7","journal-title":"Nat Neurosci"},{"key":"2657_CR74","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3389\/fneur.2018.00809","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X, Gao F, Wang D, Li C, Fu Y, He W et al (2018) Tau pathology in Parkinson\u2019s disease. Front Neurol 9:809. https:\/\/doi.org\/10.3389\/fneur.2018.00809","journal-title":"Front Neurol"},{"key":"2657_CR75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fnagi.2018.00027","volume":"10","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Shi J, Chu D, Hu W, Guan Z, Gong CX et al (2018) Relevance of phosphorylation and truncation of tau to the etiopathogenesis of Alzheimer\u2019s disease. Front Aging Neurosci 10:27. https:\/\/doi.org\/10.3389\/fnagi.2018.00027","journal-title":"Front Aging Neurosci"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-023-02657-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-023-02657-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-023-02657-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T02:04:25Z","timestamp":1704852265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-023-02657-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2657"],"URL":"https:\/\/doi.org\/10.1007\/s00401-023-02657-y","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"30 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"14"}}